Syschem India Limited is a vertically integrated manufacturer of pharmaceutical APIs and intermediates based in Kalka, Haryana, producing antibiotic APIs such as amoxicillin, ampicillin, cephalexin and cephadroxil for domestic formulators and export customers across multiple continents, with an installed capacity of ~4,200 TPA and plans to expand toward 8,000 TPA.

The company reported a strong operating inflection during 9M FY25-26 with consolidated sales rising from ₹247.48 crore to ₹406.31 crore (a 65% increase), EBITDA rising more than threefold to ₹11.75 crore and PAT swinging to a positive ₹7.74 crore for 9M, reflecting material operating leverage from higher volumes and improved product mix.

Syschem has materially increased production volumes year-on-year (1,269 MT to 1,780 MT) and reported quarterly ramp to 820 MT in Q3 FY25-26, indicating improving capacity utilization ahead of announced expansion; management explicitly states a strategic focus on increasing year-on-year production to capture rising API demand and export opportunities.

Exports are accelerating: export sales increased to ₹107.62 crore in 9M FY25-26 versus ₹90.89 crore in FY24-25, with Q3 exports doubling year-on-year, indicating successful market traction overseas and the potential to diversify revenue as domestic volumes also expand across 12 Indian states and multiple international markets.

The board emphasizes reliable supply, world-class quality and continuous innovation as core strategic pillars; with an experienced promoter-led management team and a growing client list of domestic formulators, Syschem positions itself as a mid-sized, quality-focused API supplier pursuing scale and regulatory alignment to win larger institutional customers.